102 - Comparison between 1st generation EGFR tyrosine kinase inhibitor (gefitinib) versus 2nd generation (afatinib) in EGFR-mutated non-small cell lung cancers (NSCLC) – real world experience
| Autor: | Dulloo, Sean, Almusarhed, Manar, Chen, Ryan, Akala, Oyeyemi, Varadhan, Balaji, Chauhan, Meera, Ahmed, Samreen |
|---|---|
| Zdroj: | In Lung Cancer June 2021 156 Supplement 1:S42-S43 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect